These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9989828)

  • 1. Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers.
    Soulie P; Poupon MF; Remvikos Y; Dutrillaux B; Muleris M
    Oncogene; 1999 Jan; 18(3):775-81. PubMed ID: 9989828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of gene amplification as a gain-of-function phenotype of mutant p53 proteins.
    El-Hizawi S; Lagowski JP; Kulesz-Martin M; Albor A
    Cancer Res; 2002 Jun; 62(11):3264-70. PubMed ID: 12036943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome rearrangements associated with CAD gene amplification. Experiments with cell hybrids.
    Viaggi S; Nüsse M; Ottaggio L; Bonatti S
    Mutat Res; 1992 Jan; 265(1):9-21. PubMed ID: 1370246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein alterations associated with gene amplification in cultured human and rodent cells.
    Conner EA; Wirth PJ
    Electrophoresis; 1996 Jul; 17(7):1257-64. PubMed ID: 8855414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug resistance and gene amplification potential regulated by transforming growth factor beta 1 gene expression.
    Huang A; Jin H; Wright JA
    Cancer Res; 1995 Apr; 55(8):1758-62. PubMed ID: 7712485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene amplification in a p53-deficient cell line requires cell cycle progression under conditions that generate DNA breakage.
    Paulson TG; Almasan A; Brody LL; Wahl GM
    Mol Cell Biol; 1998 May; 18(5):3089-100. PubMed ID: 9566927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability.
    Huang A; Fan H; Taylor WR; Wright JA
    Cancer Res; 1997 Nov; 57(21):4876-81. PubMed ID: 9354452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA topoisomerase II inhibition and gene amplification in V79/B7 cells.
    Di Leonardo A; Cavolina P; Maddalena A
    Mutat Res; 1993 Mar; 301(3):177-82. PubMed ID: 7679200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-copy and amplified CAD genes in Syrian hamster chromosomes localized by a highly sensitive method for in situ hybridization.
    Wahl GM; Vitto L; Padgett RA; Stark GR
    Mol Cell Biol; 1982 Mar; 2(3):308-19. PubMed ID: 6180304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [S-phase arrest associated apoptosis leads to diversities of drug resistance and mutation rate in human breast cancer cells].
    Ying H; Subrata S
    Hua Xi Yi Ke Da Xue Xue Bao; 1999 Jun; 30(2):142-5. PubMed ID: 12212041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Embryotoxicity in mice of phosphonacetyl-L-aspartic acid (PALA), a new antitumor agent. I. Embryolethal, teratogenic, and cytogenetic effects.
    Sieber SM; Botkin CC; Soong P; Lee EC; Whang-Peng J
    Teratology; 1980 Dec; 22(3):311-9. PubMed ID: 7233336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of chromosomes implicated in suppression of apoptosis in somatic cell hybrids.
    Speevak MD; Chevrette M
    Biochem Cell Biol; 1994; 72(11-12):655-62. PubMed ID: 7654340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism-based model for tumor drug resistance.
    Kuczek T; Chan TC
    Cancer Chemother Pharmacol; 1992; 30(5):355-9. PubMed ID: 1505073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant expression of basic fibroblast growth factor in NIH-3T3 cells alters drug resistance and gene amplification potential.
    Huang A; Jin H; Wright JA
    Exp Cell Res; 1994 Aug; 213(2):335-9. PubMed ID: 8050490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New RNA species is produced by alternate polyadenylation following rearrangement associated with CAD gene amplification.
    Meinkoth JL; Legouy E; Brison O; Wahl GM
    Somat Cell Mol Genet; 1986 Jul; 12(4):339-50. PubMed ID: 2426798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumorigenicity and gene amplification potentials of cyclin D1-overexpressing NIH3T3 cells.
    Asano K; Sakamoto H; Sasaki H; Ochiya T; Yoshida T; Ohishi Y; Machida T; Kakizoe T; Sugimura T; Terada M
    Biochem Biophys Res Commun; 1995 Dec; 217(3):1169-76. PubMed ID: 8554573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential gene expression in p53-mediated G(1) arrest of human fibroblasts after gamma-irradiation or N-phosphoacetyl-L-aspartate treatment.
    Seidita G; Polizzi D; Costanzo G; Costa S; Di Leonardo A
    Carcinogenesis; 2000 Dec; 21(12):2203-10. PubMed ID: 11133809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TP53 status and gene amplification in human colorectal carcinomas.
    Soulié P; Fourme E; Hamelin R; Asselain B; Salmon RJ; Dutrillaux B; Muleris M
    Cancer Genet Cytogenet; 1999 Dec; 115(2):118-22. PubMed ID: 10598144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The enhancement of the frequency of resistance to N-phosphonoacetyl-L-aspartate and methotrexate by 1-beta-D-arabinofuranosylcytosine: the effect of dipyridamole.
    Goz B; Jeffs L
    J Pharmacol Exp Ther; 1994 Aug; 270(2):480-4. PubMed ID: 8071840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of N-(phosphonacetyl)-L-aspartate resistant Chinese hamster mutants in the presence of the uridine uptake inhibitor dipyridamole.
    Tessera L; Mucciolo E; Bertoni L; Giulotto E
    Anticancer Res; 1995; 15(1):189-92. PubMed ID: 7733632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.